Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank 指定難病告示番号
1 MAPK14 31件: Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09639 Losmapimod 2件: 113, 222
2 MAPK14 31件: Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10959 Neflamapimod 1件: 8
3 IFNA1 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab 1件: 49
4 IFNA1 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab 1件: 49
5 IFNA2 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab 1件: 49
6 IFNA2 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab 1件: 49
7 IFNA4 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab 1件: 49
8 IFNA4 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab 1件: 49
9 IFNA5 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab 1件: 49
10 IFNA5 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab 1件: 49
11 IFNA6 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab 1件: 49
12 IFNA6 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab 1件: 49
13 IFNA7 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab 1件: 49
14 IFNA7 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab 1件: 49
15 IFNA8 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab 1件: 49
16 IFNA8 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab 1件: 49
17 IFNA10 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab 1件: 49
18 IFNA10 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab 1件: 49
19 IFNA13 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab 1件: 49
20 IFNA13 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab 1件: 49
21 IFNA14 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab 1件: 49
22 IFNA14 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab 1件: 49
23 IFNA16 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab 1件: 49
24 IFNA16 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab 1件: 49
25 IFNA17 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab 1件: 49
26 IFNA17 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab 1件: 49
27 IFNA21 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab 1件: 49
28 IFNA21 6件: PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab 1件: 49
29 IFNAR1 5件: PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D00745 Interferon alfa-2a 1件: 56
30 IFNAR1 5件: PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D00746 Interferon beta-1b 1件: 13
31 IFNAR1 5件: PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D02745 Interferon alfa-2b 2件: 25, 34
32 IFNAR1 5件: PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D03305 Interferon alfa 6件: 13, 25, 26, 28, 56, 96
33 IFNAR1 5件: PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D04554 Interferon beta-1a 4件: 13, 26, 96, 97
34 IFNAR1 5件: PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D10483 Peginterferon beta-1a 1件: 13
35 IFNAR1 5件: PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D11082 Anifrolumab 3件: 46, 49, 53
36 IFNAR2 5件: PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D00745 Interferon alfa-2a 1件: 56
37 IFNAR2 5件: PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D00746 Interferon beta-1b 1件: 13
38 IFNAR2 5件: PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D02745 Interferon alfa-2b 2件: 25, 34
39 IFNAR2 5件: PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D03305 Interferon alfa 6件: 13, 25, 26, 28, 56, 96
40 IFNAR2 5件: PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D04554 Interferon beta-1a 4件: 13, 26, 96, 97
41 IFNAR2 5件: PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D10483 Peginterferon beta-1a 1件: 13
42 IFNAR2 5件: PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D11082 Anifrolumab 3件: 46, 49, 53
43 IL1B 16件: Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
44 IL1B 16件: Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis D06635 Rilonacept 4件: 51, 106, 107, 266
45 IL1B 16件: Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis D09315 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269
46 IL1B 16件: Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis D09911 Gevokizumab 4件: 41, 50, 56, 269
47 IL6 17件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
48 IL6 17件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis D08976 Pomalidomide 5件: 28, 51, 85, 227, 331
49 IL6 17件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis D09669 Siltuximab 2件: 28, 331
50 IL6 17件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis D10080 Sirukumab 2件: 41, 46
51 IL6 17件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis D12487 Olokizumab 2件: 46, 96
52 JAK1 12件: PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09959 Ruxolitinib 3件: 60, 65, 228
53 JAK1 12件: PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
54 JAK1 12件: PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10308 Baricitinib 13件: 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325
55 JAK1 12件: PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10653 Peficitinib 1件: 46
56 JAK1 12件: PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10871 Filgotinib 6件: 46, 53, 96, 97, 222, 271
57 JAK1 12件: PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10944 Itacitinib 4件: 46, 51, 97, 228
58 JAK1 12件: PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10994 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271
59 JAK1 12件: PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11400 Abrocitinib 1件: 84
60 NFKB1 29件: Ras signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D01146 Iguratimod 5件: 46, 51, 53, 271, 300
61 PRKCD 5件: Vascular smooth muscle contraction, NOD-like receptor signaling pathway, Type II diabetes mellitus, Prion disease, Shigellosis D09671 Sotrastaurin 1件: 97
62 MAPK11 31件: Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09639 Losmapimod 2件: 113, 222
63 MAPK11 31件: Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10959 Neflamapimod 1件: 8
64 MAPK13 31件: Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09639 Losmapimod 2件: 113, 222
65 MAPK13 31件: Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10959 Neflamapimod 1件: 8
66 BCL2 15件: Platinum drug resistance, Sphingolipid signaling pathway, p53 signaling pathway, Protein processing in endoplasmic reticulum, PI3K-Akt signaling pathway, NOD-like receptor signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Shigellosis, Salmonella infection, Toxoplasmosis, Tuberculosis, Pathways in cancer, Prostate cancer, Small cell lung cancer D10679 Venetoclax 1件: 28
67 RELA 29件: Ras signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D12181 Edasalonexent 1件: 113
68 MAPK12 31件: Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09639 Losmapimod 2件: 113, 222
69 MAPK12 31件: Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10959 Neflamapimod 1件: 8
70 CCL2 5件: Viral protein interaction with cytokine and cytokine receptor, NOD-like receptor signaling pathway, TNF signaling pathway, Yersinia infection, Rheumatoid arthritis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
71 TNF 24件: Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D00742 Etanercept 16件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285
72 TNF 24件: Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D00754 Thalidomide 20件: 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331
73 TNF 24件: Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
74 TNF 24件: Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D02597 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271
75 TNF 24件: Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D02598 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
76 TNF 24件: Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D03441 Certolizumab pegol 8件: 37, 46, 49, 96, 97, 107, 226, 271
77 TNF 24件: Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D04358 Golimumab 8件: 46, 56, 84, 96, 97, 107, 270, 271
78 TNF 24件: Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D04687 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331
79 TNF 24件: Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D05393 Pegsunercept 1件: 46
80 TNF 24件: Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D08976 Pomalidomide 5件: 28, 51, 85, 227, 331
81 TNF 24件: Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D09944 Ozoralizumab 1件: 46
82 TYK2 5件: Osteoclast differentiation, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
83 TYK2 5件: Osteoclast differentiation, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis D11817 Deucravacitinib 3件: 49, 96, 97
84 CASR 2件: NOD-like receptor signaling pathway, Parathyroid hormone synthesis, secretion and action D03504 Cinacalcet 1件: 238